Search form

Topics:

ubmslateCL-logo-ubm

CL Mobile Menu

Diabetes Type 2

SGLT2 Inhibitor Q & A

Four questions for you to answer, four facts you need to know.

 

Diabetes Type 2

Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.

Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.

Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.

A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.

When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.

Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.

Try these 10 questions and see what you've learned during this month's special report on the nuts-and-bolts of T2DM for PCPs.

Pages

Subscribe to Diabetes Type 2 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.